User profiles for Yasemin Yozgat

Yasemin YOZGAT

Istanbul Medipol Universitesi
Verified email at medipol.edu.tr
Cited by 301

Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor

…, A Viale, G Sommer, Y Yozgat… - Proceedings of the …, 2006 - National Acad Sciences
Kit receptor-activating mutations are critical in the pathogenesis of gastrointestinal stromal
tumors (GIST). We investigated mechanisms of oncogenic Kit signaling and the …

Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor

B Bosbach, F Rossi, Y Yozgat, J Loo… - Proceedings of the …, 2017 - National Acad Sciences
Gastrointestinal stromal tumors (GISTs) predominantly harbor activating mutations in the
receptor tyrosine kinase KIT. To genetically dissect in vivo the requirement of different signal …

Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib

F Rossi, Y Yozgat, E De Stanchina, D Veach… - Molecular Cancer …, 2010 - AACR
Activating mutations in the Kit receptor tyrosine kinase are associated with gastrointestinal
stromal tumor (GIST). Imatinib inhibits Kit and is front-line therapy for GIST. However, imatinib …

N-acetylcysteine suppresses colistimethate sodium-induced nephrotoxicity via activation of SOD2, eNOS, and MMP3 protein expressions

B Ceylan, M Ozansoy, Ü Kılıç, Y Yozgat, Ç Ercan… - Renal …, 2018 - Taylor & Francis
Objective: To investigate the molecular mechanisms of colistimethate sodium-induced
nephrotoxicity and the protective effect of N-acetylcysteine (NAC) against nephrotoxicity. Methods: …

Squalene attenuates the oxidative stress and activates AKT/mTOR pathway against cisplatin-induced kidney damage in mice

…, B Elibol, Ş Ayla, MY GÜNAL, Y Yozgat… - Turkish journal of …, 2019 - journals.tubitak.gov.tr
The clinical use of cisplatin, which is a first-line anticancer agent, is highly restricted due to
its adverse effects on kidneys that lead to nephrotoxicity. Therefore, some potential reno-…

KIT receptor gain-of-function in hematopoiesis enhances stem cell self-renewal and promotes progenitor cell expansion

S Deshpande, B Bosbach, Y Yozgat, CY Park… - Stem Cells, 2013 - academic.oup.com
The KIT receptor tyrosine kinase has important roles in hematopoiesis. We have recently
produced a mouse model for imatinib resistant gastrointestinal stromal tumor (GIST) carrying …

Hexokinase 1b is a novel target for Non–small-cell lung cancer

Y Yozgat, E Karakoc, O Sahin, S Cimen, WM Rabeh… - bioRxiv, 2022 - biorxiv.org
Deregulation of glycolysis is common in non-small cell lung cancer (NSCLC). Hexokinase (HK)
enzymes catalyze the phosphoryl-group-transfer in glucose metabolism. There are a …

Mediator-RNA Polymerase II Interactions Critical for Transcriptional Activation Are Mediated by the N-terminal Half of MED14 and C-terminal Domain of RPB1

Y Baris, J Jabbar, Y Yozgat, E Cigirgan, S Bay… - bioRxiv, 2022 - biorxiv.org
Mediator is a large and evolutionarily conserved coactivator complex essential for RNA
polymerase II (Pol II)-mediated gene regulation at multiple steps of the transcription process, …

Evaluation of cardiac arrhythmias by electrocardiographic markers in pediatric patients who have tuberous sclerosis without cardiac rhabdomyoma

Y Yozgat, HD Kus, FU Kahraman, M Yuksel, CK Firat… - Archives de …, 2021 - Elsevier
Background Tuberous sclerosis (TS) is an autosomal dominant and hereditary disorder.
Cardiac rhabdomyoma and arrhythmias are the most deleterious risk factors linked to TS. …

p53-Regulated hexokinase 1b is a novel target for metabolic theraphy against non-small-cell lung cancer

Y Yozgat - 2019 - research.sabanciuniv.edu
Deregulation of glycolysis is common in non-small cell lung cancer (NSCLC). p53 controls
the cellular metabolism pathway by activating hexokinases (HKs) to increase glycolysis. HK …